Abstract
The cytogenetic analysis of plasma cell myeloma (PCM) allows stratification of patients so that prognosis may be determined and appropriate therapeutic options can be discussed. Owing to the patchy nature of the disease in the bone marrow (BM), the low proliferative activity of plasma cells and the cryptic nature of some PCM-associated cytogenetic changes, karyotypic analysis in this disease should be augmented with targeted interphase fluorescence in situ hybridization (FISH). Immunofluorescent revelation of cytoplasmic immunoglobulin light chains, together with interphase FISH (cIg-FISH), allows the identification of plasma cells within a sample so that they may be scored preferentially. This is particularly useful in situations where there are only a small percentage of plasma cells in a sample. Where an underlying myeloid disease is suspected the cIg-FISH-negative cells can be scored separately. Two methods are provided in this chapter: the technique for cIg-FISH in fresh PCM BM samples and a procedure for use in fixed cytogenetics preparations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fonseca R, Bergsagel PL, Drach J et al (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23(12):2210–2221
Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36:842–854
Greipp PR, San Miguel J, Durie BGM et al (2005) International Staging System for multiple myeloma. J Clin Oncol 23:3412–3420
Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863–2869
Fonseca R (2003) Many and multiple myeloma(s). Leukemia 17:1943–1944
Sawyer JR (2011) The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 204(1):3–12
Debes-Marun CS, Dewald GW, Bryant S et al (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17(2):427–436
Fonseca R, Blood E, Rue M et al (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11):4569–4575
Lonial S, Boise LH, Kaufman J (2015) How I treat high risk myeloma. Blood 126(13):1536–1543
Mateos M-V, San Miguel JF (2013) How should we treat newly diagnosed multiple myeloma patients? American Society of Hematology Educ Program. pp 488–495
Caligaris-Cappio F, Gregoretti MG, Merico F et al (1992) Bone marrow microenvironment and the progression of multiple myeloma. Leuk Lymphoma 8(1-2):15–22
Ross FM, Avet-Loiseau H, Ameye G et al (2012) Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97(8):1272–1277
Put N, Lemmens H, Wlodarska I et al (2010) Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosomes Cancer 49(11):991–997
Grigoriadis G, Whitehead S (2010) CD138 shedding in plasma cell myeloma. Br J Haematol 150(3):249
Drach J, Angerler J, Schuster J et al (1995) Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86:3915–3921
Ahmann GJ, Jalal SM, Juneau AL et al (1998) A novel three-colour, clone-specific fluorescence in situ hybridisation procedure for monoclonal gammopathies. Cancer Genet Cytogenet 101:7–11
Gole L, Lin A, Chua C et al (2014) Modified cIg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice. Cancer Genet 207(1-2):31–34
Kobayashi Y, Nakayama M, Uemura N et al (1999) Analysis of myelodysplastic syndrome clones arising after multiple myeloma: a case study by correlative interphase cytogenetic analysis. Jpn J Clin Oncol 29(8):374–377
Hartmann L, Biggerstaff JS, Chapman DB et al (2000) Detection of Genomic abnormalities in multiple myeloma. The application of FISH analysis in combination with various plasma cell enrichment techniques. Am J Clin Pathol 136:712–720
Ciolino AL, Tang ME, Bryant R (2009) Statistical treatment of fluorescence in situ hybridization validation data to generate normal reference ranges using excel functions. J Mol Diagn 11(4):330–333
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Moore, S., Suttle, J.M., Nicola, M. (2017). Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma. In: Wan, T. (eds) Cancer Cytogenetics. Methods in Molecular Biology, vol 1541. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6703-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6703-2_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6701-8
Online ISBN: 978-1-4939-6703-2
eBook Packages: Springer Protocols